Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2466 (Electronic) Linking ISSN: 14712466 NLM ISO Abbreviation: BMC Pulm Med Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001]-

COVID-19*/complications ; Asthma*/complications ; Asthma*/drug therapy; Humans ; Chronic Cough ; Longitudinal Studies ; SARS-CoV-2 ; Adrenal Cortex Hormones/therapeutic use ; Cough ; Dyspnea/drug therapy ; Administration, Inhalation

Background: Chronic cough is a common symptom in patients post the coronavirus disease 2019 (COVID-19). In this study, we aimed to investigate the efficacy of inhaled corticosteroids (ICS) and the clinical characteristics of patients with post-COVID-19 chronic cough during the Omicron era.
Methods: An ambispective, longitudinal cohort study was conducted that included patients with post-COVID-19 who attended the respiratory clinic at our hospital between January 1, 2023, and March 31, 2023 with a complaint of persistent cough lasting more than 8 weeks. At 30 and 60 days after the first clinic visit for post-COVID-19 chronic cough, enrolled patients were prospectively followed up. We compared the changes in symptoms and pulmonary function between patients receiving ICS treatment (ICS group) and those not receiving ICS treatment (NICS group) at the two visits.
Results: A total of 104 patients with post-COVID-19 chronic cough were enrolled in this study (ICS group, n = 51; NICS group, n = 53). The most common symptoms accompanying post-COVID-19 chronic cough were sputum (58.7%, 61/104) and dyspnea (48.1%, 50/104). Seventy-one (82.6%, 71/86) patients had airway hyperresponsiveness, and 49 patients (47.1%, 49/104) were newly diagnosed with asthma. Most patients (95.2%, 99/104) exhibited improvement at 60 days after the first visit. The pulmonary function parameters of the patients in the ICS group were significantly improved compared to the baseline values (P < 0.05), and the improvement in the FEV 1 /FVC was significantly greater than that in the NICS group (P = 0.003) after 60 days.
Conclusions: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may contribute to the pathogenesis of asthma, which could be the underlying cause of persistent cough post-COVID-19 infection. Post-COVID-19 chronic cough during the Omicron era was often accompanied by sputum, dyspnea, and airway hyperresponsiveness. ICS treatment did not have a significant impact on symptom management of post-COVID-19 chronic cough; however, it can improve impaired lung function in in these individuals.
(© 2024. The Author(s).)

J Med Virol. 2023 Jan;95(1):e28214. (PMID: 36224705)
BMC Pulm Med. 2020 Mar 20;20(1):68. (PMID: 32197604)
Clin Physiol Funct Imaging. 2009 Jan;29(1):18-23. (PMID: 18803639)
Asia Pac Allergy. 2022 Apr 25;12(2):e19. (PMID: 35571551)
Lancet Respir Med. 2021 Jul;9(7):763-772. (PMID: 33844996)
Chest. 1988 Mar;93(3):580-6. (PMID: 3342669)
Allergy Asthma Immunol Res. 2023 May;15(3):395-405. (PMID: 37075801)
Int J Biol Macromol. 2022 Apr 15;204:161-168. (PMID: 35074332)
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Jan 15;46:E002. (PMID: 36642495)
J Asthma. 2023 Jun;60(6):1221-1226. (PMID: 36279253)
Eur Respir J. 2021 Apr 29;57(4):. (PMID: 33419891)
Zhonghua Jie He He Hu Xi Za Zhi. 2022 Jan 12;45(1):13-46. (PMID: 35000304)
Pediatr Pulmonol. 2022 Oct;57(10):2455-2463. (PMID: 35775163)
Chest. 2006 Jan;129(1 Suppl):138S-146S. (PMID: 16428703)
Int J Infect Dis. 2023 Mar;128:102-111. (PMID: 36587841)
J Clin Med. 2022 Nov 29;11(23):. (PMID: 36498626)
Lancet. 2021 Sep 4;398(10303):843-855. (PMID: 34388395)
Clin Infect Dis. 2023 Jul 26;77(2):194-202. (PMID: 36905145)
Eur Respir J. 2017 Apr 26;49(4):. (PMID: 28446552)
Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30. (PMID: 15817806)
J Med Virol. 2020 Apr;92(4):399-400. (PMID: 31967329)
Ann Intern Med. 2021 Apr;174(4):576-578. (PMID: 33175566)
Lancet Respir Med. 2022 Sep;10(9):863-876. (PMID: 35568052)
Eur Respir J. 2017 Jan 3;49(1):. (PMID: 28049168)
Int J Gen Med. 2021 Feb 23;14:571-580. (PMID: 33654424)
Eur Respir J. 2014 Nov;44(5):1149-55. (PMID: 25186267)
Eur Respir Rev. 2021 Dec 15;30(162):. (PMID: 34911694)
Lancet Infect Dis. 2023 Apr;23(4):393-395. (PMID: 36967698)
Eur Respir J. 1998 Jan;11(1):126-32. (PMID: 9543281)
J Allergy Clin Immunol Pract. 2023 Mar;11(3):825-835.e3. (PMID: 36566779)
Lancet Respir Med. 2022 Jun;10(6):545-556. (PMID: 35397798)
J Thorac Dis. 2022 Jun;14(6):2079-2088. (PMID: 35813767)
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. (PMID: 31613151)
Sci Rep. 2021 Aug 9;11(1):16144. (PMID: 34373540)
Lancet Respir Med. 2021 May;9(5):533-544. (PMID: 33857435)
BMC Infect Dis. 2022 Mar 12;22(1):244. (PMID: 35279094)
Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508)

2020YFC0860900 National Key Research and Development Program of China; 2020YFC0860900 National Key Research and Development Program of China; 2020YFC0860900 National Key Research and Development Program of China; 2020YFC0860900 National Key Research and Development Program of China; 2020YFC0860900 National Key Research and Development Program of China; 20QNPY115 the Top-Notch Project for Youth Training

Keywords: Chronic cough; Inhaled corticosteroid (ICS); Long COVID; Omicron; Viral infection related-asthma; post-COVID-19 syndrome

0 (Adrenal Cortex Hormones)

SARS-CoV-2 variants

Date Created: 20240328 Date Completed: 20240329 Latest Revision: 20240330

20240330

PMC10967081

10.1186/s12890-024-02937-7

38539172